Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Rd Life Sciences LLC currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, indicating a concentrated prosecution focus at this stage. The portfolio's activity is confined to 1 distinct art unit, which suggests a narrow technical scope for the pending matter. For a practitioner, this concentration means that the outcome of the current portfolio status depends entirely on the interactions with this specific examiner in a single art unit.
FIEBIG, RUSSELL G is identified as the busiest examiner for the company, currently overseeing 1 busiest examiner pending action. This 1 busiest examiner pending action represents the total pending workload for the company. Because there is only 1 distinct examiner and 1 distinct art unit involved, the company's immediate legal strategy is focused on a single point of contact within the USPTO. This lack of diversification in examiners or art units means that the company's current patent prospects are tied to the evaluation of FIEBIG, RUSSELL G within that 1 distinct art unit. Practitioners should focus on the specific preferences and history of this examiner to anticipate the trajectory of the pending action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598827 | COMPOSITIONS COMPRISING METAL-COMPLEXED PLANT COMPOUNDS AND USES THEREOF | FIEBIG, RUSSELL G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598827 | COMPOSITIONS COMPRISING METAL-COMPLEXED PLANT COMPOUNDS AND USES THEREOF | FIEBIG, RUSSELL G | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18598827 | COMPOSITIONS COMPRISING METAL-COMPLEXED PLANT COMPOUNDS AND USES THEREOF | FIEBIG, RUSSELL G | 1655 | §103§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRd Life Sciences LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Russell G Fiebig has the most, with 1 of Rd Life Sciences LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
